MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 571111 | Name: Remoxipride hydrochloride (hydrate)

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Remoxipride hydrochloride (hydrate) is an antipsychotic and potent D2DR (dopamine D2 receptor) antagonist.

Chemical Structure

Remoxipride hydrochloride (hydrate)
Remoxipride hydrochloride (hydrate)
CAS#117591-79-4 (HCl hydrate)

Theoretical Analysis

MedKoo Cat#: 571111

Name: Remoxipride hydrochloride (hydrate)

CAS#: 117591-79-4 (HCl hydrate)

Chemical Formula: C16H26BrClN2O4

Exact Mass: 424.0764

Molecular Weight: 425.75

Elemental Analysis: C, 45.14; H, 6.16; Br, 18.77; Cl, 8.33; N, 6.58; O, 15.03

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
80125-14-0 (free base) 73220-03-8 (HCl) 117591-79-4 (HCl hydrate)
Synonym
Remoxipride hydrochloride (hydrate)
IUPAC/Chemical Name
Benzamide, 3-bromo-N-((1-ethyl-2-pyrrolidinyl)methyl)-2,6-dimethoxy-, monohydrochloride, monohydrate, (S)-
InChi Key
SPFVHFBNXPARTR-IDMXKUIJSA-N
InChi Code
InChI=1S/C16H23BrN2O3.ClH.H2O/c1-4-19-9-5-6-11(19)10-18-16(20)14-13(21-2)8-7-12(17)15(14)22-3;;/h7-8,11H,4-6,9-10H2,1-3H3,(H,18,20);1H;1H2/t11-;;/m0../s1
SMILES Code
O=C(NC[C@H]1N(CC)CCC1)C2=C(OC)C=CC(Br)=C2OC.[H]Cl.[H]O[H]
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 425.75 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Yisak W, Farde L, von Bahr C, Nilsson LB, Fredriksson G, Ogenstad S. Interaction study between remoxipride and biperiden. Psychopharmacology (Berl). 1993;111(1):27-32. PubMed PMID: 7870930. 2: Ma G, Friberg LE, Movin-Osswald G, Karlsson MO. Comparison of the agonist-antagonist interaction model and the pool model for the effect of remoxipride on prolactin. Br J Clin Pharmacol. 2010 Dec;70(6):815-24. doi: 10.1111/j.1365-2125.2010.03758.x. PubMed PMID: 21175437; PubMed Central PMCID: PMC3014065. 3: Movin-Osswald G, Boelaert J, Hammarlund-Udenaes M, Nilsson LB. The pharmacokinetics of remoxipride and metabolites in patients with various degrees of renal function. Br J Clin Pharmacol. 1993 Jun;35(6):615-22. PubMed PMID: 8329289; PubMed Central PMCID: PMC1381605. 4: Stevens J, Ploeger BA, Hammarlund-Udenaes M, Osswald G, van der Graaf PH, Danhof M, de Lange EC. Mechanism-based PK-PD model for the prolactin biological system response following an acute dopamine inhibition challenge: quantitative extrapolation to humans. J Pharmacokinet Pharmacodyn. 2012 Oct;39(5):463-77. doi: 10.1007/s10928-012-9262-4. Epub 2012 Jul 12. PubMed PMID: 22791078. 5: Lapierre YD, Ancill R, Awad G, Bakish D, Beaudry P, Bloom D, Chandrasena R, Das M, Durand C, Elliott D, et al. A dose-finding study with remoxipride in the acute treatment of schizophrenic patients. J Psychiatry Neurosci. 1992 Oct;17(4):134-45. PubMed PMID: 1450186; PubMed Central PMCID: PMC1188438. 6: Widerlöv E, Andersson U, von Bahr C, Nilsson MI. Pharmacokinetics and effects on prolactin of remoxipride in patients with tardive dyskinesia. Psychopharmacology (Berl). 1991;103(1):46-9. PubMed PMID: 1672458. 7: Rammsayer T, Gallhofer B. Remoxipride versus haloperidol in healthy volunteers: psychometric performance and subjective tolerance profiles. Int Clin Psychopharmacol. 1995 Mar;10(1):31-7. PubMed PMID: 7622802. 8: Vartiainen H, Leinonen E, Putkonen A, Lang S, Hagert U, Tolvanen U. A long-term study of remoxipride in chronic schizophrenic patients. Acta Psychiatr Scand. 1993 Feb;87(2):114-7. PubMed PMID: 8447237. 9: Stevens J, Ploeger BA, van der Graaf PH, Danhof M, de Lange EC. Systemic and direct nose-to-brain transport pharmacokinetic model for remoxipride after intravenous and intranasal administration. Drug Metab Dispos. 2011 Dec;39(12):2275-82. doi: 10.1124/dmd.111.040782. Epub 2011 Sep 8. PubMed PMID: 21903866. 10: Ogren SO, Florvall L, Hall H, Magnusson O, Angeby-Möller K. Neuropharmacological and behavioural properties of remoxipride in the rat. Acta Psychiatr Scand Suppl. 1990;358:21-6. Review. PubMed PMID: 1978483. 11: Högberg T, Rämsby S, de Paulis T, Stensland B, Csöregh I, Wägner A. Solid state conformations and antidopaminergic effects of remoxipride hydrochloride and a closely related salicylamide, FLA 797, in relation to dopamine receptor models. Mol Pharmacol. 1986 Oct;30(4):345-51. PubMed PMID: 2945089. 12: Lewander T. Overcoming the neuroleptic-induced deficit syndrome: clinical observations with remoxipride. Acta Psychiatr Scand Suppl. 1994;380:64-7. Review. PubMed PMID: 7914053. 13: Movin-Osswald G, Hammarlund-Udenaes M, Von Bahr C, Eneroth P, Walton-Bowen K. Influence of the dosing interval on prolactin release after remoxipride. Br J Clin Pharmacol. 1995 May;39(5):503-10. PubMed PMID: 7669486; PubMed Central PMCID: PMC1365057. 14: Ogren SO, Hall H, Köhler C, Magnusson O, Lindbom LO, Angeby K, Florvall L. Remoxipride, a new potential antipsychotic compound with selective antidopaminergic actions in the rat brain. Eur J Pharmacol. 1984 Jul 20;102(3-4):459-74. PubMed PMID: 6149133. 15: Yisak W, von Bahr C, Farde L, Grind M, Mattila M, Ogenstad S. Drug interaction studies with remoxipride. Acta Psychiatr Scand Suppl. 1990;358:58-62. PubMed PMID: 1978492. 16: Phanjoo AL, Link C. Remoxipride versus thioridazine in elderly psychotic patients. Acta Psychiatr Scand Suppl. 1990;358:181-5. PubMed PMID: 1978481. 17: Wålinder J, Holm AC. Experiences of long-term treatment with remoxipride: efficacy and tolerability. Acta Psychiatr Scand Suppl. 1990;358:158-63. PubMed PMID: 1978477. 18: Awad AG, Lapierre YD, Jostell KG. Selective dopamine D2 antagonist and prolactin response in acute schizophrenia--results from remoxipride studies. The Canadian Remoxipride Study Group. Prog Neuropsychopharmacol Biol Psychiatry. 1990;14(5):769-77. PubMed PMID: 2149882. 19: den Boer JA, Westenberg HG. Atypical neuroleptics in acute schizophrenia: a double-blind comparative study of remoxipride and haloperidol. Psychopharmacol Bull. 1990;26(1):99-107. PubMed PMID: 1973547. 20: King DJ, Blomqvist M, Cooper SJ, Doherty MM, Mitchell MJ, Montgomery RC. A placebo controlled trial of remoxipride in the prevention of relapse in chronic schizophrenia. Psychopharmacology (Berl). 1992;107(2-3):175-9. PubMed PMID: 1352050.

View History

Fenimide

Fenimide

Ro 23-7637

Ro 23-7637

Remoxipride

Remoxipride

ND-378

ND-378

6-Alkynyl-fucose

6-Alkynyl-fucose

Cavidine

Cavidine